|
Commercial and Pipeline Insight - Opioids - Short acting and anti-abuse technologies set to fragment and grow the market (Datamonitor)
Market: Healthcare and Medical
Published Date: 26/03/2008
Market Research Report Title: Commercial and Pipeline Insight - Opioids - Short acting and anti-abuse technologies set to fragment and grow the market
Table of Contents: View
Report Type: Market Report
Country: Global
Number of Pages: 233
|
Enquire about Report |
Summary: Introduction
The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market players instigate lifecycle management strategies to retain value.
Scope
Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.Analysis of patient potential, unmet needs and clinical trial design in the opioid market.Overview of key marketed brands, late- and early-stage pipeline drugs.Identification of future market events that are expected to affect opioid revenues.Highlights
Short-acting opioids represent good in-licensing opportunities for companies with large sales and marketing resources. This market is expected to triple in value over the next 10 years, driven by Cephalon′s Fentora for use in breakthrough pain, and supported by other new short-acting fentanyl formulations.The long-acting opioid market was valued at over $3 billion in 2007, and is due to grow until the patent expiry of market leader OxyContin in 2011. After a short lived decline, market growth will be stimulated by the launch of anti-abuse formulations, a technical development anticipated to create a $1 billion market.The topical market represents an opportunity for companies to enter a comparatively underserved market. Although Johnson and Johnson′s market leading Duragesic (fentanyl patch) has faced generic opposition since 2005, sales remain relatively strong due to brand strength and the lack of branded competition.Reasons to Purchase
Benchmark key late-stage pipeline opioids against current market leading brands.Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.Understand unmet needs and opportunities in the opioid market based on key opinion leader comments.
Reports are normally delivered on the same day, via email, if purchased by debit/credit card. Reports purchased by invoice will be released when payment has been received. When you place an order through Google Checkout, Google Checkout will display a price approximation in your local currency. Keep in mind that you'll still be charged in the currency displayed on companiesandmarkets.com. Your debit/credit card company might convert the charge to your local currency and may also add additional fees that are not reflected in the approximate price displayed.
www.companiesandmarkets.com is a central source of market research reports from the world’s leading analysts and report publishers. Companiesandmarkets.com contains a comprehensive range of specialised market research reports from leading publishers for all market sectors.
